Vicore Pharma to Spotlight IPF Program at Oppenheimer Healthcare Conference

The latest update is out from Vicore Pharma Holding AB ( (SE:VICO) ).

Vicore Pharma will participate in the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, where CEO Ahmed Mousa and VP of IR and Communications Megan Richards will deliver a company presentation and hold one-on-one investor meetings. The appearance underscores Vicore’s efforts to raise its profile among healthcare investors as it advances buloxibutid through mid-stage clinical development for idiopathic pulmonary fibrosis, potentially strengthening its positioning in the competitive respiratory drug development space.

The company’s engagement at this high-visibility conference may help communicate the clinical and regulatory progress of its lead ATRAG program to the broader market and key stakeholders. By highlighting the disease-modifying potential of buloxibutid and its FDA designations, Vicore aims to reinforce investor confidence and support for its strategy in addressing serious unmet needs in fibrotic lung disease.

The most recent analyst rating on (SE:VICO) stock is a Hold with a SEK11.50 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.

More about Vicore Pharma Holding AB

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company focused on developing a novel class of angiotensin II type 2 receptor agonists to treat respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. Its lead candidate, buloxibutid, is an oral, first-in-class ATRAG that has Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is being evaluated in a global 52-week Phase 2b ASPIRE trial in IPF.

Average Trading Volume: 650,388

Technical Sentiment Signal: Sell

Current Market Cap: SEK3B

See more data about VICO stock on TipRanks’ Stock Analysis page.